Patents by Inventor Jacqueline Elizabeth Shea

Jacqueline Elizabeth Shea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8329163
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: December 11, 2012
    Assignee: Merial Limited
    Inventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois Xavier Le Gros
  • Publication number: 20120009218
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Application
    Filed: April 20, 2011
    Publication date: January 12, 2012
    Applicant: Merial Limited
    Inventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
  • Patent number: 7955600
    Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: June 7, 2011
    Assignee: Emergent Product Development UK Limited
    Inventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
  • Patent number: 7943125
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: May 17, 2011
    Assignee: Merial Limited
    Inventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
  • Patent number: 7887816
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: February 15, 2011
    Assignee: Emergent Product Development UK Limited
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 7700104
    Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: April 20, 2010
    Assignee: Emergent Product Development UK Limited
    Inventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
  • Publication number: 20090252766
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Application
    Filed: October 7, 2008
    Publication date: October 8, 2009
    Inventors: Helen Rachel CROOKE, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
  • Patent number: 7449178
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: November 11, 2008
    Assignee: Merial Limited
    Inventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
  • Publication number: 20080274139
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Application
    Filed: February 1, 2007
    Publication date: November 6, 2008
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 7211264
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: May 1, 2007
    Assignee: Emergent Product Development UK Limited
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 6951732
    Abstract: A series of genes from Streptococcus pyogenes are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: October 4, 2005
    Assignee: VMAX Ltd.
    Inventors: Enda Elizabeth Clarke, Liqing Zhou, Jacqueline Elizabeth Shea, Robert Graham Feldman, David William Holden
  • Patent number: 6936425
    Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SP12 gene locus, wherein at least one gene of the SP12 locus is inactivated, wherein the inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is the attenuated gram-negative cell, wherein the cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for the antigen, wherein the cell is capable of expressing the nucleic acid molecule or capable of causing the expression of the nucleic acid molecule in a target cell.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: August 30, 2005
    Assignees: Microscience Limited, Imperial College Innovations Limited
    Inventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
  • Patent number: 6846667
    Abstract: The present invention is based on the identification of a series of virulence genes in E. coli K1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: January 25, 2005
    Assignee: Microscience, Ltd.
    Inventors: Helen Rachel Crooke, Enda Elizabeth Clarke, Paul Howard Everest, Gordon Dougan, David William Holden, Jacqueline Elizabeth Shea, Robert Graham Feldman
  • Publication number: 20040203039
    Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.
    Type: Application
    Filed: January 23, 2004
    Publication date: October 14, 2004
    Applicants: Microscience Limited, Imperial College Innovations Limited
    Inventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
  • Publication number: 20040191866
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Application
    Filed: April 8, 2004
    Publication date: September 30, 2004
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 6756042
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: June 29, 2004
    Assignee: Microscience, Ltd.
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Publication number: 20040033586
    Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.
    Type: Application
    Filed: April 3, 2003
    Publication date: February 19, 2004
    Inventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
  • Publication number: 20030072769
    Abstract: A series of genes from Streptococcus pyogenes are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.
    Type: Application
    Filed: September 23, 2002
    Publication date: April 17, 2003
    Inventors: Enda Elizabeth Clarke, Liqing Zhou, Jacqueline Elizabeth Shea, Robert Graham Feldman, David William Holden
  • Publication number: 20030059442
    Abstract: Double mutant Salmonella microorganisms help prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. Various specific combinations of mutants are beneficial.
    Type: Application
    Filed: September 23, 2002
    Publication date: March 27, 2003
    Inventors: Gordon Dougan, David William Holden, Joseph David Santangelo, Jacqueline Elizabeth Shea, Francis Richard Brennan
  • Patent number: 6342215
    Abstract: A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of: (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism; (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant; (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment; (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms; (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique m
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: January 29, 2002
    Assignees: Imperial College Innovations Limited, Microscience Limited
    Inventors: David William Holden, Jacqueline Elizabeth Shea, Michael Hensel